Nektar Therapeutics (NKTR) Cash & Equivalents (2010 - 2026)

Nektar Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $149.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 284.58% year-over-year to $149.6 million; the TTM figure through Mar 2026 stood at $149.6 million (up 284.58% YoY), while the FY2025 annual figure was $15.1 million, down 65.84% from the prior year.
• Cash & Equivalents was $149.6 million for Q1 2026 at Nektar Therapeutics, up from $15.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $149.6 million in Q1 2026 to a low of $15.1 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $59.2 million across 5 years, with a median of $48.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents sank 65.84% in 2025, then soared 284.58% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $88.2 million in 2022, then sank by 60.02% to $35.3 million in 2023, then advanced by 25.44% to $44.3 million in 2024, then sank by 65.84% to $15.1 million in 2025, then jumped by 889.53% to $149.6 million in 2026.
• The last three Cash & Equivalents figures came in at $149.6 million (Q1 2026), $15.1 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.